Endoscopy 2014; 46(07): 619-624
DOI: 10.1055/s-0034-1365505
Case report/series
© Georg Thieme Verlag KG Stuttgart · New York

Routine use of Hemospray for gastrointestinal bleeding: prospective two-center experience in Switzerland

Michael C. Sulz
1   Department of Gastroenterology and Hepatology, Kantonspital St. Gallen, Switzerland
,
Remus Frei
1   Department of Gastroenterology and Hepatology, Kantonspital St. Gallen, Switzerland
,
Christa Meyenberger
1   Department of Gastroenterology and Hepatology, Kantonspital St. Gallen, Switzerland
,
Peter Bauerfeind
2   Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital of Zurich, Switzerland
,
Gian-Marco Semadeni
1   Department of Gastroenterology and Hepatology, Kantonspital St. Gallen, Switzerland
,
Christoph Gubler
2   Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital of Zurich, Switzerland
› Author Affiliations
Further Information

Publication History

submitted 31 December 2013

accepted after revision 20 January 2014

Publication Date:
25 April 2014 (online)

Preview

Hemospray (Cook Medical, Winston-Salem, North Carolina, USA) is a hemostatic agent recently introduced for the management of upper gastrointestinal bleeding (GIB). To date, there is little experience with this fairly new hemostatic tool. The aim of this case series was to reflect the use and effectiveness of Hemospray as a treatment option in GIB in everyday clinical practice at two tertiary referral centers. Consecutive patients (n = 16) with active GIB of various origins were treated with Hemospray. The rate of successful initial hemostasis was 93.75 % (15 /16; salvage therapy 92.85 % [13/14]; monotherapy 100 % [2 /2]). The rebleeding rate within 7 days was 12.5 % (2/16). One patient, in whom interventional radiology also failed, had to undergo surgery as salvage therapy. The effectiveness of Hemospray in the management of GIB in various clinical situations is promising. Future multicenter randomized prospective trials for clearly defined bleeding situations are needed for greater generalizability of case series findings.